tert-butyl 4-(tert-butylcarbamoyl)piperazine-1-carboxylate | 253175-40-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(tert-butylcarbamoyl)piperazine-1-carboxylate
• CAS: 253175-40-5
• 化学式: C₁₄H₂₇N₃O₃
• mdl: MFCD24389552
• 分子量: 285.387
• InChiKey: GIBWFHNQLQLVEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(tert-butylcarbamoyl)piperazine-1-carboxylate 在 碳酸氢钠 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-tert-Butylcarbamoyl-piperazine-1-carbonyl chloride
  参考文献：
  名称：

  Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors

  摘要：

  A series of N1-activated C4-carboxy azetidinones was prepared and tested as inhibitors of human tryptase. The key stereochemical and functional features required for potency, serine protease specificity and aqueous stability were determined. From these studies compound 2, BMS-262084, was identified as a potent and selective tryptase inhibitor which, when dosed intratracheally in ovalbumin-sensitized guinea pigs, reduced allergen-induced bronchoconstriction and inflammatory cell infiltration into the lung. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00688-1
• 作为产物：
  描述：

  N-Boc-哌嗪 在 水 、 sode de l'acide trichloroisocyanurique 作用下， 以 水 、 异丙醇 为溶剂， 反应 1.67h， 生成 tert-butyl 4-(tert-butylcarbamoyl)piperazine-1-carboxylate
  参考文献：
  名称：

  一种基于绿色，基于异氰化物的三组分反应方法，用于合成多取代的脲和硫脲

  摘要：

  提出了一种基于一锅，基于异氰化物的多组分方案，该方案从仲胺到（硫）脲衍生物开始使用，并用于构建多样化的27元化学文库。在绿色相容的微波辅助条件下，以高达85％的产率获得形成的N，N'-多取代的（硫代）脲。

  DOI：

  10.1016/j.tetlet.2017.11.053

文献信息

• Beta lactam compounds and their use as inhibitors of tryptase
  申请人：Bristol-Myers Squibb Co.

  公开号：US06335324B1

  公开（公告）日：2002-01-01

  Compounds of the formulas: are disclosed. These compounds inhibit tryptase as well as other enzyme systems or are selective tryptase inhibitors and are useful as antiinflammatory agents particularly in the treatment of chronic asthma.

  这些化合物的结构式已被披露。这些化合物抑制色胺酸蛋白酶以及其他酶系统，或者是选择性色胺酸蛋白酶抑制剂，并且在特别是治疗慢性哮喘方面作为抗炎药物是有用的。
• [EN] AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS<br/>[FR] INHIBITEURS D'AMIDINO ET GUANIDINO AZETIDONONE TRYPTASE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：WO1999067215A1

  公开（公告）日：1999-12-29

  (EN) Compounds of formulae (I), (II), (III).(FR) L'invention concerne des composés correspondant aux formules (I), (II) et (III).

  这是中文翻译： (EN) Compounds of formulae (I), (II), (III). 对应于公式(I)，(II)，(III)的化合物。 (FR) L'invention concerne des composés correspondant aux formules (I), (II) et (III). 该发明涉及对应于公式(I)，(II)，(III)的化合物。
• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20090012094A1

  公开（公告）日：2009-01-08

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文介绍了一种包含二芳胺结构特征的化合物。还介绍了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的制药组合物和药物。本文还介绍了使用这种化合物、制药组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
  申请人：Molteni Valentina

  公开号：US20070149538A1

  公开（公告）日：2007-06-28

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了包含二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的药物组合物和药物。本文还描述了使用这种化合物、药物组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Chianelli Donatella

  公开号：US20110053952A1

  公开（公告）日：2011-03-03

  The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-raf or b-raf kinases.

  本发明提供了式(I)的化合物及其制药组合物，它们可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或失调的激酶活性相关的疾病或症状的方法。在某些实施例中，本发明提供使用这些化合物治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、Abl、BCR-Abl、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-RAf或b-RAf激酶异常活化的疾病或症状的方法。